Skip to main content

Table 2 Baseline characteristics of participants and non-participants

From: Randomized controlled trial of the effects of high intensity and low-to-moderate intensity exercise on physical fitness and fatigue in cancer survivors: results of the Resistance and Endurance exercise After ChemoTherapy (REACT) study

Characteristics

HI

LMI

WLC

Non-participants

n = 91

n = 95

n = 91

n = 479

Sociodemographic

Age, mean (SD) years

54 (11.0)

53 (11.3)

54 (10.9)

55 (11.6)

Sex, n (%) male a

18 (20)

17 (18)

20 (22)

77 (16)

Married/living together, n (%) yes

73 (80) f

87 (92) f

72 (79) f

 

Education, n (%) b

 Low

19 (21)

12 (13)

16 (18)

 

 Intermediate

37 (41)

43 (46)

42 (46)

 

 High

34 (38)

38 (40)

33 (36)

 

Being employed, n (%)

 Employed

54 (59)

56 (58)

57 (63)

 

 Not employed

25 (28)

22 (23)

19 (21)

 

 Retirement

12 (13)

17 (18)

15 (17)

 

Smoking, n (%) yes c

7 (8)

5 (5)

5 (6)

 

Comorbidity, n (%) yes

12 (13)

8 (8)

10 (11)

 

Sport history, n (%) yes d

45 (50)

61 (65)

49 (54)

 

Exercise during chemotherapy, n (%) yes b

21 (23)

21 (22)

10 (11)

 

Clinical

Diagnosis, n (%) e

 Breast

62 (68)

62 (65)

57 (63)

309 (65)

 Colon

15 (17)

19 (20)

15 (17)

85 (18)

 Ovarian

4 (4)

3 (3)

5 (6)

23 (5)

 Lymphoma

9 (10)

9 (9)

8 (9)

47 (10)

 Cervix

0 (0)

2 (2)

2 (2)

12 (3)

 Testis

1 (1)

0 (0)

4 (4)

4 (1)

Stage of disease, n (%)

 Stage I–II

68 (75)

57 (60)

62 (68)

 

 Stage II–IV

23 (25)

38 (40)

29 (32)

 

Type of treatment, n (%) yes

 Surgery

83 (91)

87 (92)

80 (88)

 

 Radiation therapy

46 (51)

41 (43)

48 (53)

 

 Surgery + radiation therapy

41 (45)

39 (41)

46 (51)

 

 Immunotherapy

16 (18)

25 (26)

18 (20)

 

 Hormonal therapy

45 (50)

40 (42)

43 (47)

 

Type of chemotherapy, n (%)

 TAC

39 (43)

33 (34)

31 (34)

 

 FEC

7 (8)

7 (7)

5 (6)

 

 TAC/FEC combinations

15 (17)

21 (22)

17 (19)

 

 Capecitabine and oxaliplatin

8 (9)

11 (12)

7 (8)

 

 Oxaliplatin combinations

7 (8)

8 (8)

7 (8)

 

 Carboplatin and paclitaxel

4 (4)

4 (4)

10 (11)

 

 CHOP

5 (6)

6 (6)

7 (8)

 

 ABVD

4 (4)

2 (2)

2 (2)

 

 Cisplatin

0

2 (2)

1 (1)

 

 BEP

1 (1)

0

3 (3)

 

 Other

1 (1)

1 (1)

1 (1)

 
  1. HI, High intensity; LMI, Low-to-moderate intensity; WLC, Wait list control; FEC, Fluorouracil, epirubicin, cyclophosphamide; TAC, Taxotere, adriamycin, cyclophosphamide; CHOP, Cyclophosphamide, doxorubicin, vincristine, prednisone; ABVD, Doxorubicin, bleomycin, vinblastine, dacarbazine; BEP, Bleomycin, etoposide, cisplatin
  2. a n-4 (non-participants)
  3. b n-3
  4. c n-4
  5. d n-1
  6. e n-1 (non-participants)
  7. f P <0.05